CYP2D6-debrisoquine hydroxylase gene polymorphism in multiple system atrophy

✍ Scribed by V. Planté-Bordeneuve; O. Bandmann; G. Wenning; N. P. Quinn; S. E. Daniel; Prof. A. E. Harding

• Publisher: John Wiley and Sons
• Year: 1995
• Tongue: English
• Weight: 200 KB
• Volume: 10
• Category: Article
• ISSN: 0885-3185
• DOI: 10.1002/mds.870100307

✦ Synopsis

Molecular genetic studies of the cytochrome P450 system enzyme CYP2D6, which hydroxylates debrisoquine, have indicated an excess of mutant alleles in large series of patients with Parkinson's disease (PD) when compared with controls. We have investigated C YP2D6 polymorphism in 91 patients with multiple system atrophy (MSA) in order to determine if this finding is specific to PD or if there is similar evidence of genetic susceptibility to neurotoxicity in MSA. The distribution of CYP2D6 alleles was not signifcantly different between MSA patients and controls, and there were fewer poor metabolisers in the MSA group than in the control group.